Myeloid Cell Leukemia Sequence 1 Protein
"Myeloid Cell Leukemia Sequence 1 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the myeloid leukemia factor (MLF) protein family with multiple alternatively spliced transcript variants encoding different protein isoforms. In hematopoietic cells, it is located mainly in the nucleus, and in non-hematopoietic cells, primarily in the cytoplasm with a punctate nuclear localization. MLF1 plays a role in cell cycle differentiation.
| Descriptor ID |
D064549
|
| MeSH Number(s) |
D12.644.360.075.718.984 D12.776.476.075.718.968 D12.776.624.664.700.169.500
|
| Concept/Terms |
Myeloid Cell Leukemia Sequence 1 Protein- Myeloid Cell Leukemia Sequence 1 Protein
- Myeloid Cell Leukemia Sequence 1
- Myeloid Cell Factor-1
- Cell Factor-1, Myeloid
- Factor-1, Myeloid Cell
- Myeloid Cell Factor 1
- Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1
- Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1
|
Below are MeSH descriptors whose meaning is more general than "Myeloid Cell Leukemia Sequence 1 Protein".
Below are MeSH descriptors whose meaning is more specific than "Myeloid Cell Leukemia Sequence 1 Protein".
This graph shows the total number of publications written about "Myeloid Cell Leukemia Sequence 1 Protein" by people in this website by year, and whether "Myeloid Cell Leukemia Sequence 1 Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 4 | 4 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 7 | 7 |
| 2008 | 0 | 6 | 6 |
| 2009 | 0 | 4 | 4 |
| 2010 | 0 | 8 | 8 |
| 2011 | 0 | 8 | 8 |
| 2012 | 0 | 6 | 6 |
| 2013 | 2 | 4 | 6 |
| 2014 | 4 | 3 | 7 |
| 2015 | 3 | 4 | 7 |
| 2016 | 1 | 2 | 3 |
| 2017 | 3 | 7 | 10 |
| 2018 | 0 | 3 | 3 |
| 2019 | 4 | 1 | 5 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 1 | 2 |
| 2022 | 2 | 8 | 10 |
| 2023 | 0 | 8 | 8 |
| 2024 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myeloid Cell Leukemia Sequence 1 Protein" by people in Profiles.
-
A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies. Clin Cancer Res. 2024 Nov 01; 30(21):4844-4855.
-
Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia. Cell Rep Med. 2024 Jun 18; 5(6):101585.
-
Apoptosis Pathway-Associated Proteins Are Frequently Expressed in Melanoma: A Study of 32 Cases With Focus on Acral Lentiginous Melanoma. Am J Dermatopathol. 2024 Jul 01; 46(7):410-415.
-
Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins. Cell Death Dis. 2023 11 02; 14(11):714.
-
BCL-xL Targeting to Induce Apoptosis and to Eliminate Chemotherapy-Induced Senescent Tumor Cells: From Navitoclax to Platelet-Sparing BCL-xL PROTACs. Cancer Res. 2023 11 01; 83(21):3501-3503.
-
Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Discov. 2023 07 07; 13(7):1656-1677.
-
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J. 2023 06 29; 13(1):101.
-
Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability. Oncotarget. 2023 06 21; 14:653-655.
-
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J. 2023 04 24; 13(1):57.
-
Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia. Blood. 2023 03 30; 141(13):1610-1625.